- Home
- TKNO vs INBX Comparison
TKNO vs INBX Comparison
Compare TKNO & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TKNO
- INBX
- Stock Information
- Founded
- TKNO 1996
- INBX 2010
- Country
- TKNO United States
- INBX United States
- Employees
- TKNO N/A
- INBX N/A
- Industry
- TKNO Medicinal Chemicals and Botanical Products
- INBX Biotechnology: Pharmaceutical Preparations
- Sector
- TKNO Health Care
- INBX Health Care
- Exchange
- TKNO Nasdaq
- INBX Nasdaq
- Market Cap
- TKNO 244.7M
- INBX 237.5M
- IPO Year
- TKNO 2021
- INBX 2020
- Fundamental
- Price
- TKNO $5.45
- INBX $15.64
- Analyst Decision
- TKNO Buy
- INBX Hold
- Analyst Count
- TKNO 2
- INBX 1
- Target Price
- TKNO $5.00
- INBX N/A
- AVG Volume (30 Days)
- TKNO 122.3K
- INBX 111.7K
- Earning Date
- TKNO 11-07-2024
- INBX 08-13-2024
- Dividend Yield
- TKNO N/A
- INBX N/A
- EPS Growth
- TKNO N/A
- INBX N/A
- EPS
- TKNO N/A
- INBX 118.83
- Revenue
- TKNO $34,940,000.00
- INBX $1,687,000.00
- Revenue This Year
- TKNO $3.22
- INBX N/A
- Revenue Next Year
- TKNO $14.88
- INBX N/A
- P/E Ratio
- TKNO N/A
- INBX $0.13
- Revenue Growth
- TKNO N/A
- INBX 24.26
- 52 Week Low
- TKNO $1.16
- INBX $10.80
- 52 Week High
- TKNO $5.47
- INBX $18.95
- Technical
- Relative Strength Index (RSI)
- TKNO 62.45
- INBX 52.98
- Support Level
- TKNO $4.76
- INBX $14.67
- Resistance Level
- TKNO $5.07
- INBX $16.35
- Average True Range (ATR)
- TKNO 0.36
- INBX 0.58
- MACD
- TKNO 0.02
- INBX -0.08
- Stochastic Oscillator
- TKNO 98.27
- INBX 57.74
About TKNO Alpha Teknova Inc.
Alpha Teknova Inc provides critical reagents that enable the discovery, development, and production of biopharmaceutical products such as drug therapies, novel vaccines, and molecular diagnostics. Its product offerings include pre-poured media plates for cell growth and cloning, liquid cell culture media and supplements for cellular expansion, and molecular biology reagents for sample manipulation, resuspension, and purification. It derives maximum revenue from United States.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.